Read on Twitter
KEYNOTE-158 study out in Lancet Oncology, Pembrolizumab for TMB>10- most data time date we have seen since FDA approval, key aspects include tumor types studied https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30445-9/fulltext
From FDA package insert we have tumor types that were studied, notice no breast or colon or prostate patients so is true unknown for most of cancer types
Which survival curve and waterfall plot is TMB>10 ?
Left with more questions than answers in sense patients that benefited, but neither TMB (or PD-L1 historically) can reliability identify outside a few specific known settings (ie KN24 in nsclc for pdl1>50%).Perhaps rare cancers in which aPD1 unstudied with truly high TMB (1/2)
And shows how much further we have to go in the immune biomarker space to make sure we are able to best guide patients in terms of their best treatment options. But it should come as no surprise that given lack of progress in IO biomarker space,IO drug discovery is equally halted
*to date
